Juan Felipe Roldán Pardo

Partner

Partner of the Firm, with more than 16 years of experience advising local and foreign clients. In his day-to-day he advises private companies and high net worth individuals in the conduction of their business and special projects. Juan Felipe focuses his practice on cross-border transactions, M&A, foreign direct investment, business structuring, financing, and complex dispute resolution and in particular in shareholder litigation.

Throughout his practice, Juan Felipe has been positioning himself as a key player in the Corporate and M&A mid-market, bringing a young and agile team to the table, but ensuring a top-notch professional service, skills, and a business mindset comparable to those of any big law firms in the Country. Juan Felipe has been recognized as such by colleagues, clients, and relevant stakeholders, as he has been nominated as next generation partner in the latest editions of Legal 500 and as an outstanding lawyer in the area by Leaders League, and Best Lawyers.

Juan Felipe also has relevant experience in the real sector, as he is a member of the investment committee of Private Equity Fund – Cattleya, is a member of the Board of Directors of Ban100 S.A., of Aritmetika S.A.S., and of the Colombian Chinese Chamber of Investment and Commerce.

Juan Felipe holds a JD from Universidad de los Andes (Bogotá, Colombia), he coursed studies in private international law at Carlos III University of Madrid, he holds a LLM from Northwestern University, where he graduated with honors Magna Cum Laude, and holds a minor in Business Administration from Instituto de la Empresa of Madrid.

Additionally, Juan Felipe lived in China for over three (3) years, where he studied Mandarin as a fellow of the People’s Republic of China, at Beijing Language and Culture University, and later worked as a foreign associate at Sinowing Law LLP. Hence Juan Felipe is a reference in the Colombian – Chinese relationships and oversees our China desk.

Juan Felipe speaks Spanish, English, Italian and Mandarin.